Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,298.70down ₹40.30 (1.72%)BSE ₹2,308.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹2,339.00.
30 Oct: open ₹2,336.00, high ₹2,337.30, low ₹2,291.30
52-week range of traded prices to 30 Oct 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹64,875 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 36.08
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.34
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.17
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,28,88751.5% delivered
Glenmark Pharmaceuticals dividends
18 filed, newest first.
Sep 2025
May 2024
24 May · Dividend
May 2023
Jun 2020
May 2019
May 2018
May 2017
Jul 2016
May 2016
Aug 2015
May 2015
May 2014
8 May · Dividend
Board of Directors of the Company at its meeting held on May 08, 2014, inter alia, has recommended Dividend @ 200% i.e. Rs. 2/- per share (face value Re. 1/-) on the Equity Share Capital of the Company for the financial year 2013-2014 subject to the approval of the Shareholders at the ensuing Annual General Meeting.
May 2013
8 May · Dividend
Board of Directors of the Company at its meeting held on May 07, 2013, has recommended dividend @ 200% i.e. Rs. 2/- per share (face value Re. 1/-) on the Equity Share Capital of the Company for the financial year 2012-2013 subject to the approval of the Shareholders at the ensuing Annual General Meeting.
May 2012
8 May · Dividend
Board of Directors of the Company at its meeting held on May 08, 2012 has recommended Dividend @ 200% i.e. 2/- per share (face value Re. 1/-) on the Equity Share Capital of the Company for the financial year 2011-2012 subject to the approval of the Shareholders at the ensuing Annual General Meeting.
May 2011
10 May · Dividend
Board of Directors of the Company at its meeting held on May 10, 2011, has Recommend Dividend @ 40% i.e. Re.0.40 per share (face value Re.1/-) on the Equity Share Capital of the Company for the financial year 2010-2011 subject to the approval of the Shareholders at the ensuing Annual General Meeting.
May 2010
28 May · Dividend
Board of Directors, at their meeting held on May 28, 2010, has recommended Dividend @ 40% i.e. Re.0.40 per share (face value Re.1/-) on the Equity Share Capital of the Company for the financial year 2009-2010 subject to the approval of Shareholders at the Annual General Meeting.
Jun 2009
27 Jun · Dividend
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Board of Directors of the Company at its Meeting held on June 26, 2009 has recommended dividend @ Re.0.40 (face value Rs.1/-) on the Equity Share Capital of the Company for the financial year 2008-2009 subject to the approval of the Shareholders at the Annual General Meeting.
Oct 2007
31 Oct · Dividend
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Board of Directors at their Meeting held on October 31, 2007 has declared Interim Dividend @70% on equity Share capital.